Compare GTIM & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTIM | NCNA |
|---|---|---|
| Founded | 1987 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 13.8M |
| IPO Year | 1990 | 2017 |
| Metric | GTIM | NCNA |
|---|---|---|
| Price | $1.16 | $3.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 89.4K | 78.2K |
| Earning Date | 02-05-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $141,630,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.10 | $2.78 |
| 52 Week High | $2.65 | $268.00 |
| Indicator | GTIM | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.91 | 42.46 |
| Support Level | $1.14 | $3.25 |
| Resistance Level | $1.20 | $3.81 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 13.33 | 25.00 |
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers; chicken; frozen custard; slides and drinks.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.